EP0063879A2

Modified nucleotides and methods of preparing and using same.

Abstract

Compounds having the structure: wherein B represents a purine, 7-deazapurine, or pyrimidine moiety covalently bonded to the C1-position of the sugar moiety, provided that when B is purine or 7-deazapurine. it is attached at the N'-position of the purine or 7-deazapurine and when 8 is pyrimidine, it is attached at the N'-position;wherein A represents a moiety consisting of at least three carbon atoms which is capable of forming a detectable complex with a polypeptide when the compound is Incorporated into a double-stranded ribonucleic acid. deoxyribonucleic acid duplex, or DNA-RNA hybrid; wherein the dotted line represents a chemical linkage joining B and A. provided that if B is purine, the linkage is attached to the 8-position of the purine, if B is 7. deazapurine, the linkage is attached to the 7-position of the deazapurine, and if B is pyrimidine, the linkage is attached to the 5-position of the pyrimidine; and wherein each of x. y and z represents either directly, or when incorporated into oligo- and polynucleotides, provide probes which are widely useful. Applications include detection and localization of polynucleotide sequences in chromosomes, fixed cells. tissue sections, and cell extracts. Specific applications include chromosomal karyotyping, clinical diagnosis of nucleic acid-containing etiological agents, e.g. bacteria, viruses. or fungi, and diagnosis of genetic disorders.

EP0063879A2, drawing sheet 1
Sheet 1 of 70

Term

Term ended

Projected expiry passed 6 April 2002, 24.5 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

55 claims: 47 independent, 8 dependent

  1. 1
    A compound having the structure:wherein B represents a purine, 7-deazapurine or pyrimidine moiety covalently bonded to the C1' -position of the sugar moiety, provided that when B is purine or 7-deazapurine, it is attached at the N9-position of the purine or deazapurine, and when B is pyrimidine, it is attached at the Nl-position;wherein A represents a moiety consisting of at least three carbon atoms which is capable of forming a detectable complex with a polypeptide when the compound is incorporated into a double-stranded ribonucleic acid, deoxyribonucleic acid duplex, or DNA-RNA hybrid;wherein the dotted line represents a linkage or group joining B and A, provided that if B is purine, the linkage is attached to the 8-position of the purine, if B is 7-deazapurine, the linkage is attached to the 7-position of the deazapurine, and if B is pyrimidine, the linkage is attached to the 5-position of the pyrimidine;andwherein each of x, y and z represents
  2. 2
    A compound having the structure:wherein each of B, B', and B" represents a purine, deazapurine, or pyrimidine moiety covalently bonded to the C1'- position of the sugar moiety, provided that whenever B, B', or B" is purine or deazapurine, it is attached at the N9- position of the purine or deazapurine, and whenever B, B', or B" is pyrimidine, it is attached at the N1-position;wherein A represents a moiety consisting of at least three carbon atoms which is capable of forming a detectable complex with a. polypeptide when the compound is incorporated into a double-stranded duplex formed with a complementary ribonucleic or deoxyribonucleic acid molecule.wherein the dotted line represents a chemical linkage or group joining B and A, provided that if B is purino, tho linkage is attached to the 8-position of the purine, if B is 7-deazapurine, the linkage is attached to the 7-position of the deazapurine, and if B is pyrimidine, the linkage is attached to the 5-position of the pyrimidine;wherein z represents H- or HO-;andwherein m and h represent integers from 0 up to about 100,000.
  3. 3
    A compound in accordance with Claim 1 or 2 wherein A is a hapten.
  4. 4
    A compound in accordance with Claim 1 or 2 wherein A is a ligand.
  5. 5
    A compound in accordance with Claim 1 or 2 wherein A is biotin.
  6. 6
    . A compound in accordance with Claim 1 or 2 wherein A is iminobiotin.
  7. 7
    A compound in accordance with Claim 1 wherein A is an organic moiety containing at least five carbon atoms.
  8. 8
    A compound in accordance with Claim 1 wherein A is a non-aromatic organic moiety.
  9. 9
    A compound in accordance with Claim 1 or 2 wherein the chemical linkage represented by the dotted line includes an olefinic bond at the α-position relative to B.
  10. 10
    A compound in accordance with Claim 1 or 2 wherein the chemical.linkage includes the moiety -CH2-NH-.
  11. 11
    A compound in accordance with Claim 9 wherein the ole- .finic chemical linkage is -CH=CH-CH2-NH-.
  12. 12
    A compound in accordance with Claim 9 wherein the olefinic chemical linkage is
  13. 13
    A compound in accordance with Claim 1 wherein the chemical linkage is selected from or includes a moiety selected from the group consisting of
  14. 14
    A compound in accordance with Claim 1 wherein B is uracil, cytosine, deazaadenine, or deazaguanine.
  15. 15
    A compound in accordance with Claim 1 wherein x is y is HO-, and z is HO-
  16. 16
    A compound in accordance with Claim 1 wherein x is y is HO-, and z is HO-.
  17. 17
    A compound in accordance with Claim 1 wherein x is y. is HO-, and z is HO-.
  18. 18
    A compound in accordance with Claim 1 wherein x is y is HO-, and z is H-.
  19. 19
    A compound in accordance with Claim 1 wherein x.is y is HO-, and z is H-.
  20. 20
    A compound in accordance with Claim 1 wherein x is y is HO-, and z is H-.
  21. 21
    A compound in accordance with Claim 1 wherein x is , y is and z is HO-.
  22. 22
    A compound in accordance with Claim 1 wherein x is y is and z is HO-.
  23. 23
    A compound in accordance with any of Claims 15 to 22, wherein A is biotin.
  24. 24
    A compound in accordance with any of Claims 15 to 22 wherein A is iminobiotin.
  25. 25
    A compound in accordance with any of Claims 15 to 24 wherein the chemical linkage is -CH=CH-CH2-NH-.
  26. 26
    A compound in accordance with any of Claims 15 to 24 wherein the chemical linkage is
  27. 27
    A compound in accordance with Claim 2 wherein m and n are not simultaneously 0.
  28. 28
    A compound in accordance with Claim 2 wherein B is uracil, cytosine, deazaadenine, or deazaguanine.
  29. 29
    A method of preparing a modified nucleotide having the structure:wherein B represents a purine, 7-deazapurine or pyrimidine moiety covalently bonded to the C 1'-position of the sugar moiety, provided that when B'is purine or 7-deazapurine, it is attached at the N9-position of the purine or deazapuring, and when B is pyrimidine, it is attached at the N1-position;wherein A represents a moiety consisting of at least three carbon atoms which is capable of forming a detectable complex with a polypeptide when the compound is incorporated into a double-stranded ribonucleic acid, deoxyribonucleic acid duplex, DNA-RNA hybrid;wherein the dotted line represents a chemical linkage joining B and A, provided that if B is purine, the linkage is attached to the 8-position of the purine, if B is 7-deazapurine, the linkage is attached to the 7-position of the deazapurine, and if B is pyrimidine, the linkage is attached to the 5-position of the pyrimidine;andwherein each of.z, y, and z represents comprising the steps of:(a) reacting a compound having the structure: with a mercuric salt in a suitable solvent under suitable conditions so as to form a mercurated compound having the structure: (b) reacting said mercurated compound with a chemical moiety reactive with the -Hg+ portion of said mercurated compound and represented by the formula ···N, said reaction being carried out in'an aqueous solvent and in the presence of K2PdCl4 under suitable conditions so as to form a compound having the structure: wherein N is a reactive terminal functional group or is A;and(c) recovering said compound as said modified nucleotide when N is A, or when N is a reactive terminal group, reacting said compound with a compound having the structure M-A, wherein M represents a functional group reactive with N in an aqueous solvent under suitable conditions so as to form said modified nucleotide which is then recovered.
  30. 30
    A method.in accordance with Claim 25 wherein said chemical moiety represented by the formula ···N is
  31. 31
    A method in accordance with Claim 25 wherein said chemical moiety.represented by the formula ···N is
  32. 32
    A method of making a compound in accordance with Claim 2 comprising an enzymatically polymerization of nucleotide triphosphates having the structure wherein Q represents B···A, B', or B", and one of x and y represents , and the other of x and y represents HO- in the presence of a nucleic acid template under suitable conditions so as to form said com- . pound.
  33. 34
    A method in accordance with Claim 33 wherein ···N comprises thiol, carboxylic acid, epoxide, and amine.
  34. 35
    A method in accordance with Claim 33 wherein said chemical moiety represented by the formula ···N is
  35. 36
    A method in accordance with Claim 33 wherein said chemical moiety represented by the formula ···N is
  36. 37
    A method in accordance with Claim 33 wherein said chemical moiety represented by the formula ···N is
  37. 38
    A method in accordance with Claim'33 wherein said chemical moiety represented by the formula ···N is
  38. 39
    A method of detecting a compound in accordance with Claim 1 which comprises contacting said compound with a polypeptide capable of forming a complex therewith under suitable conditions so as to form said complex, said polypepetide being capable of or including a moiety which can be detected when said complex of said compound and said polypeptide is formed, and detecting said complex using an appropriate detection technique.
  39. 40
    A chemical complex comprising a compound in accordance with Claim 1 and a polypeptide capable of forming said complex with said compound.
  40. 41
    A method of detecting a compound in accordance with Claim 2 which comprises contacting said compound with a polypeptide capable of forming a complex therewith under suitable conditions so as to form said complex, said polypeptide including a moiety which can be detected when said complex of said compound and said polypeptide is formed, and detecting said complex using an appropriate detection technique.
  41. 42
    A chemical complex comprising a compound in accordance with Claim 2 and a polypeptide capable of forming said complex with said compound.
  42. 43
    A chemical complex in accordance with Claim 42 wherein said polypeptide includes a moiety which can be detected, being a fluorescent dye, electron dense reagent, or enzyme capable of depositing an insoluble reaction product.
  43. 51
    A method of chromosomal karyotyping which comprises preparing a series of modified polynucleotides corresponding to a series of defined genetic sequences located on chromosomes, said polynucleotides including compounds in accordance with Claim 1, contacting said polynucleotides with deoxyriboxyribonucleic acid obtained from chromosomes so as to form hybrid duplexes, contacting each of said duplexes with a polypeptide which is capable of forming a complex with each such duplex, said polypeptides including moieties which can be detected when said complexes are formed, and determing the location of each complex on said chromosomes so as to thereby determine the location of said genetic sequences on said chromosomes.
  44. 52
    A method of detecting a polynucleotide which includes the terminal polynucleotide sequence poly A which comprises preparing a modified poly U molecule in which at least one uracil moiety has been modified by chemical addition at the 5-position of a moiety A consisting of at least three carbon atoms which is capable of forming a detectable complex with a polypeptide when the modified uracil moiety is incorporated into a double-stranded poly A-poly U duplex, forming such a poly A-poly U duplex by contacting said polynucleotide containing said poly A sequence with said modified poly U molecule under suita- conditions, and detecting resulting duplexes so as to thereby detect said polynucleotide.
  45. 53
    A method of tumor or cancer cell identification which comprises detecting malignant cells by detecting abnormal hormonal receptor sites associated therewith by providing:(1) a compound in accordance with Claim 1 in which x or z is H- or HO- and the other two of x, y and z are reacted to form the cyclic moiety. (2) and binding said compound to the said sites under suitable conditions permitting binding, disrupting said cells to produce cell surface fragments to which said compound is bound, separately recovering said cell surface fragment, and identifying the same so as to identify said hormone receptor sites.
  46. 54
    A method of diagnosing a tumor cell which comprises preparing a polynucleotide which is complementary to a messenger ribonucleic acid synthesized from a deoxyribonucleic acid gene sequence associated with production of a polypeptide diagnostic for said tumor cell and includes a compound in accordance with Claim 1, introducing said polynucleotide into said cell under suitable conditions so as to permit said polynucleotide to hybridize with said deoxyribonucleic acid gene sequence, and determining whether said polynucleotide hybridizes.
  47. 55
    A diagnostic kit useful for determining the presence of a nucleic acid - containing organism such as a bacterium which comprises a compound in accordance with Claim 2 which is complementary to all or a unique portion of the nucleic acid contained in said organism and a polypeptide capable of forming a detectable complex therewith.
Independent claims47